Psychosis and synthetic cannabinoids.
Huiqiong Deng, Christopher D. Verrico, Thomas R Kosten, David A Nielsen
Psychiatry Research October 2018 DOI: 10.1016/j.psychres.2018.08.012 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Cannabis |
| Keywords | K2 Psychoactive substances Psychosis Spice Synthetic cannabinoids |
| Key findings | Reports indicate that consuming synthetic cannabinoid products can induce psychotic symptoms, including new-onset psychosis and psychotic relapses. The authors argue that the relationship between synthetic cannabinoids and psychosis is more complex than any single chemical component can explain and may not be a simple extension of the effects of cannabis or natural cannabinoids. |
Abstract
Synthetic cannabinoid (SC) products have gained popularity as abused drugs over the past decade in many countries. The SCs broadly impact psychological state (e.g., mood, suicidal thoughts and psychosis) and physiological functions (e.g., cardiovascular, gastrointestinal and urinary). This review is about the effects of SCs on psychotic symptoms in clinical settings and the potentially relevant chemistry and mechanisms of action for SCs. Induction of psychotic symptoms after consuming SC products were reported, including new-onset psychosis and psychotic relapses. The role of SCs in psychosis is more complex than any single chemical component might explain, and these effects may not be a simple extension of the typical effects of cannabis or natural cannabinoids.
Comparable studies
Other narrative reviews on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Causal association between cannabis and psychosis: examination of the evidence | 2004 | Review | |
| Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. General (historical and pharmacological review) | 2018 | Review | |
| Psychiatric effects of cannabis | 2001 | Review | |
| Beyond THC: The New Generation of Cannabinoid Designer Drugs | 2011 | Review | |
| Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | 2006 | Review |
Citations in the library
Cited by 16
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Cannabis and Psychosis Through the Lens of DSM-5 International Journal of Environmental Research and Public Health October 28, 2019
- The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective Frontiers in Psychiatry November 20, 2019
- New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects. International Journal of Molecular Sciences August 31, 2024
- Therapeutic Potential of Natural Psychoactive Drugs for Central Nervous System Disorders: A Perspective from Polypharmacology Current Medicinal Chemistry December 13, 2019
and 11 more in the library
Cites 18
- Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases The British Journal of Psychiatry November 30, 2005
- Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia Translational Psychiatry November 27, 2012
- Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology October 2016
- Effect of JWH-250, JWH-073 and their interaction on "tetrad", sensorimotor, neurological and neurochemical responses in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry June 3, 2016
- Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology December 2013
and 13 more in the library